Author:
Schefler Amy C.,Kim Ryan S.
Publisher
Springer International Publishing
Reference124 articles.
1. Murray TG, Latiff A, Villegas VM, Gold AS. Aflibercept for radiation maculopathy study: a prospective, randomized clinical study. Ophthalmol Retina. 2019;3(7):561–6. https://doi.org/10.1016/j.oret.2019.02.009.
2. Fallico M, Reibaldi M, Avitabile T, Longo A, Bonfiglio V, Chronopoulos A, et al. Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1547–54. https://doi.org/10.1007/s00417-019-04347-6.
3. Finger PT, Chin KJ. Intravitreous ranibizumab (lucentis) for radiation maculopathy. Arch Ophthalmol. 2010;128(2):249–52. https://doi.org/10.1001/archophthalmol.2009.376.
4. Kim IK, Lane AM, Jain P, Awh C, Gragoudas ES. Ranibizumab for the prevention of radiation complications in patients treated with proton beam irradiation for choroidal melanoma. Trans Am Ophthalmol Soc. 2016;114:T2.
5. Schefler AC, Fuller D, Anand R, Fuller T, Moore C, Munoz J, et al. Randomized trial of monthly versus as-needed intravitreal Ranibizumab for radiation retinopathy-related macular edema: 1-year outcomes. Am J Ophthalmol. 2020;216:165–73. https://doi.org/10.1016/j.ajo.2020.03.045.